In conclusion, the present results suggest for the first-time autoantibodies against AT1 receptors and ACE2 as a new mechanism of progression of dopaminergic degeneration and neuroinflammation in PD, via activation of the brain RAS proinflammatory axis. The gene discussed is ACE2; the disease is Parkinson disease.